Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001415889-23-000697.pdf
0001415889-23-000697.rtf
0001415889-23-000697.xls
3/A

An amendment to a 3 filing. Non-EDGAR filing

 View HTML
0001104659-15-033273.pdf
0001104659-15-033273.rtf
0001104659-15-033273.xls
3/A

An amendment to a 3 filing. Non-EDGAR filing

 View HTML
0001179110-16-022254.pdf
0001179110-16-022254.rtf
0001179110-16-022254.xls
3/A

An amendment to a 3 filing. Non-EDGAR filing

 View HTML
0001415889-22-003505.pdf
0001415889-22-003505.rtf
0001415889-22-003505.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000315066-15-002590.pdf
0000315066-15-002590.rtf
0000315066-15-002590.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001012975-15-000330.pdf
0001012975-15-000330.rtf
0001012975-15-000330.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-15-014505.pdf
0001179110-15-014505.rtf
0001179110-15-014505.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-15-014506.pdf
0001179110-15-014506.rtf
0001179110-15-014506.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-15-014787.pdf
0001179110-15-014787.rtf
0001179110-15-014787.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000315066-15-003307.pdf
0000315066-15-003307.rtf
0000315066-15-003307.xls